CSG has acquired Alzchem Group AG for an undisclosed amount, marking a significant corporate transaction in the specialty chemicals sector. Alzchem, a globally active specialty chemicals company, is a market leader across most of its fields. In 2023, the company reported Group sales of EUR 540.6 million and EBITDA of EUR 81.4 million, underscoring its robust financial performance. Alzchem is known for developing solutions addressing critical global developments such as climate change, population growth, and increasing life expectancy.
Alzchem’s comprehensive product portfolio includes dietary supplements, precursors for PCR tests, and pharmaceutical raw materials, alongside offerings in human and animal nutrition, agriculture, fine chemicals, metallurgy, and renewable energies. The company operates five production sites across Germany and Sweden and maintains three sales companies in the USA, China, and England, employing approximately 1,690 people. Its strategic positioning in responding to global trends highlights its long-term growth potential.
This acquisition is strategically significant for CSG, as it gains a well-established and profitable entity with strong intellectual property and deep market penetration in essential chemical applications. The move is expected to enhance CSG’s capabilities in high-growth areas like nutrition, healthcare, and sustainable solutions. Synergies are anticipated through expanded market access for Alzchem’s specialized products, optimization of operational efficiencies, and the integration of complementary research and development efforts.
The combined entity is poised to capitalize on Alzchem’s proven expertise in developing innovative chemical solutions for pressing global challenges. This corporate acquisition positions CSG to strengthen its competitive standing and drive future growth by leveraging Alzchem’s established market leadership and its commitment to sustainable development and addressing societal needs.